Acadia Pharmaceuticals (ACAD) Net Cash Flow (2010 - 2026)

Acadia Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at $104.5 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 202.56% year-over-year to $104.5 million in Q1 2026; TTM through Mar 2026 was $63.5 million, a 295.74% increase from a year earlier, with the FY2025 full-year figure at -$142.8 million, down 206.58% from the prior year.
• Net Cash Flow advanced to $104.5 million in Q1 2026 per ACAD's latest filing, from -$81.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $176.1 million in Q1 2023 and bottomed at -$180.6 million in Q2 2023.
• The 5-year median for Net Cash Flow is $4.4 million (2025), against an average of $8.1 million.
• Across the five-year window, Net Cash Flow soared 366.79% in 2022 and tumbled 733.51% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$40.0 million in 2022, then surged by 326.26% to $90.5 million in 2023, then soared by 81.82% to $164.5 million in 2024, then plunged by 149.81% to -$81.9 million in 2025, then jumped by 227.53% to $104.5 million in 2026.
• Per Business Quant, the three latest ACAD Net Cash Flow figures stand at $104.5 million (Q1 2026), -$81.9 million (Q4 2025), and $4.4 million (Q3 2025).